7 completed, 2 not yet recruiting, 2 withdrawn, 1 recruiting. 14 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 7, Not yet recruiting 2, Withdrawn 2, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 4 | Completed 2, Not yet recruiting 1, Withdrawn 1 |
Follow Filoviridae Infections: new trials by email Literature Review of Filoviridae Infections trials Research Report on Filoviridae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the Congo Candidate BDBV vaccine, Active comparator - Ebola Hemorrhagic Fever, Bundibugyo Virus Disease | Phase 2 / Phase 3 | Not yet recruiting | Jean-Pierre Van geertruyden | 3620 | 2026-10-20 | 2026-10-05 |
| EBOla Post-Exposure Prophylaxis Ervebo, Inmazeb - Ebola Virus Disease | Phase 3 | Not yet recruiting | ANRS, Emerging Infectious Diseases | 160 | 2026-09-01 | 2026-01-22 |
| Immunity Induced by VSV-EBOV and Assessment of a Booster Dose in Individuals at Potential Occupational Risk for Exposure ERVEBO® (rVSV∆G-ZEBOV-GP) - Ebola Vaccine | Phase 3 | Withdrawn | Universitätsklinikum Hamburg-Eppendorf | 2026-06-01 | 2026-06-04 | |
| Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC Zabdeno® booster, Ervebo® booster - Ebola Virus Disease | Phase 3 | Recruiting | Institute of Tropical Medicine, Belgium | 624 | 2025-02-25 | 2025-03-18 |
| A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants Ad26.ZEBOV, MVA-BN-Filo, Placebo - Ebola | Phase 3 | Completed | Janssen Vaccines & Prevention B.V. | 974 | 2020-02-18 | 2025-05-25 |
| Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC Ad26.ZEBOV, MVA-BN-Filo vaccine - Ebola Virus Disease | Phase 3 | Unknown | London School of Hygiene and Tropical Medicine | 20426 | 2019-11-14 | 2021-11-23 |
| Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine rVSVΔG-ZEBOV-GP - Ebola Virus Disease | Phase 3 | Completed | Epicentre | 500 | 2018-05-28 | 2018-12-19 |
| Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Ad26.ZEBOV, MVA-BN-Filo - Hemorrhagic Fever, Ebola | Phase 3 | Terminated | Janssen Vaccines & Prevention B.V. | 677 | 2016-05-31 | 2024-01-02 |
| Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo Ad26.ZEBOV, MVA-BN-Filo, MenACWY - Ebola Virus Disease | Phase 3 | Completed | Janssen Vaccines & Prevention B.V. | 1023 | 2015-09-30 | 2022-07-18 |
| A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3 - Healthy | Phase 3 | Completed | Crucell Holland BV | 329 | 2015-09-21 | 2025-06-22 |
| A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants Ad26.ZEBOV 5*10^10 viral particles (vp), Ad26.ZEBOV 2*10^10 (vp), Ad26.ZEBOV 0.8*10^10 (vp) - Healthy | Phase 3 | Completed | Janssen Vaccines & Prevention B.V. | 525 | 2015-09-21 | 2025-05-25 |
| STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola) rVSVΔG-ZEBOV - Hemorrhagic Fever, Ebola | Phase 2 / Phase 3 | Completed | Centers for Disease Control and Prevention | 8651 | 2015-04-01 | 2018-04-05 |
| Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea Convalescent Plasma - Hemorrhagic Fever, Ebola | Phase 2 / Phase 3 | Completed | Institute of Tropical Medicine, Belgium | 606 | 2015-02-01 | 2019-07-22 |
| Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola) Best Supportive Care, Best Supportive Care + Amiodarone - Ebola Virus Disease | Phase 2 / Phase 3 | Withdrawn | Emergency NGO Onlus | 2014-12-01 | 2015-10-06 |
Hemorrhagic Fever, Ebola (14) · Hemorrhagic Fevers, Viral (3)
Infections (14) · Mononegavirales Infections (14) · RNA Virus Infections (14) · Virus Diseases (14) · Hemorrhagic Fevers, Viral (11)
Amiodarone (1) · MenACWY (1) · atoltivimab, maftivimab, and odesivimab-ebgn drug combination (1)
Janssen Vaccines & Prevention B.V. (4) · Institute of Tropical Medicine, Belgium (2) · ANRS, Emerging Infectious Diseases (1) · Centers for Disease Control and Prevention (1) · Crucell Holland BV (1) · Emergency NGO Onlus (1) · Epicentre (1) · Jean-Pierre Van geertruyden (1) · London School of Hygiene and Tropical Medicine (1) · Universitätsklinikum Hamburg-Eppendorf (1)
Democratic Republic of the Congo (5) · United States (4) · Sierra Leone (3) · Guinea (2) · Uganda (2) · Burkina Faso (1) · France (1) · Germany (1) · Kenya (1) · Liberia (1) · Tanzania (1) · United Kingdom (1)
Daniel Bausch, MD, PhD (1) · Deborah Watson-Jones, MD, PhD (1) · Jean-Jacques Muyembe-Tamfum, MD, PhD (1) · Johan van Griensven, MD (1) · Marylyn M Addo, Prof (1) · Mohamed Samai, MBChB,PhD (1) · Niankoye Haba, MD (1) · Wim Adriaensen, Prof. (1)
PMID 34930928, PMID 26735992, PMID 26768570, PMID 27959686, PMID 28647166, PMID 29788339, PMID 29788340, PMID 29788341, PMID 29788342, PMID 29788343, PMID 29788345, PMID 29788346, PMID 29788347, PMID 29788348, PMID 29788349, PMID 29895178, PMID 32017677, PMID 34529962, PMID 34529963, PMID 35260458, PMID 36208978, PMID 37631885, PMID 38400193, PMID 38603720
2015 (1), 2019 (1)